Navigation Links
BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Date:7/25/2008

EXTON, Pa., July 25 /PRNewswire/ -- BioTrends Research Group, Inc. released its 10th quarterly Nephrology TreatmentTrends(TM) publication, a syndicated report offering comprehensive insight into the management of renal anemia and bone and mineral metabolism in Chronic Kidney Disease (CKD) and Dialysis. The report provides information from 182 US Nephrologists -- data were collected through an online survey fielded in June 2008.

In the renal anemia market, while the use of ESAs remains consistent in hemodialysis patients compared to the same quarter last year, for the second quarter in a row, Nephrologists report a significant decrease in the percent of Stage 3 and Stage 4 CKD patients treated with ESAs compared to the previous year. And, approximately one-third of Nephrologists report that their ESA use has decreased specifically due to managed care policies. While there have been no significant changes in market share year over year (Amgen's Epogen remains the market leader in dialysis and Ortho Biotech's Procrit and Amgen's Aranesp continue to battle for market leader position in CKD), there are indicators of brand switching, particularly related to office stocking and managed care reimbursement. Despite the decreased use of ESAs in CKD, Nephrologists do not expect any significant change in treatment prevalence with ESAs in the next three months.

Unlike the use of ESAs in CKD, the use of IV Iron has not changed significantly since last year -- but treatment prevalence with IV iron in CKD remains much lower than treatment prevalence with ESAs. In part, this seems related to the fact that very few Nephrologists stock IV iron (36% compared to the 73% who stock ESAs) -- primary reasons for not stocking IV iron are "limited staffing resources" and "logistics of buying and billing." While American Regent's Venofer continues to hold its position as market leader in both dialysis and CKD, the majority of Nephrologists continue to view Venofer and Wats
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
2. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
4. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
5. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
6. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
7. ARUP Laboratories Releases ARUP Consult(R) 2.0
8. Rabobank Releases Annual North American Food & Agribusiness Outlook
9. National Nanotechnology Initiative releases new strategic plan
10. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
11. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Corporation is,pleased to announce it has obtained US FDA ... C-QUR Edge(TM) V-Patch and C-QUR Lite(TM),V-Patch., These new ... and,reinforcement of soft tissue, including hernia repair -- a ... each year. This novel,technology combines Atrium,s ProLite Ultra(TM) polypropylene ...
... ENMD-2076, ROCKVILLE, Md., May 8 ... developing therapeutics for,the treatment of cancer and ... has joined the University of Colorado Cancer,Center ... ENMD-2076 in advanced cancer,patients. Dr. Geoffrey Shapiro, ...
... May 7, 2008 / b3c newswire / – ... entered into a joint agreement to supply customers ... complex structures. , Under the agreement, CRELUX and ... crystal-grade protein kinase portfolio, optimized and quality-controlled for ...
Cached Biology Technology:Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 2CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 3
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Everyone wants to live in the nicest possible house, ... at Tufts University,s School of Arts and Sciences and ... locate new and improved housing using previously unknown social ... experiments and computer models to uncover some surprising new ...
... Here,s another reason to kick the soda habit. New ... ( http://www.fasebj.org ) shows that high levels of phosphates ... than once thought. That,s because researchers found that the ... phosphate levels may also increase the prevalence and severity ...
... 23, 2010) Moffitt Cancer Center announces steadily growing ... for selecting chemotherapy for Non Small Lung Cancer patients. ... with lung cancer. The ERCC1 Analysis measures ERCC1 ... The correlation between ERCC1 levels and therapy ...
Cached Biology News:Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists 2Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer 2
... are complete ready-to-use reagents for the isolation ... specifically formulated for the isolation of genomic ... specifically formulated for the isolation of genomic ... DNAzol Reagents can be used for restriction ...
Apoptosis Detection Systems and Reagents...
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: